Search results
Found 30426 matches for
Oxford, UK: 23 May, 2018: Orbit Discovery Ltd, an Oxford, UK-based biotech company developing an industry-leading peptide identification and optimisation platform, today announced the closing of a £6.9M Series A Financing. The round was led by Oxford Sciences Innovation who were joined by new investors RT Ventures, Borealis Ventures, Perivoli Innovations, along with further investment from all existing investors and Oxford University. Additionally, Borealis Managing Partner Phil Ferneau and Oxford Investment Consultants’ Partner James Mallinson join Orbit’s Board of Directors.
Royston Group - AI-based Analysis of the Bone Marrow; Integrating Spatial Transcriptomics & Multiplexed Imaging To Improve the Assessment of Blood Cancer (Funding Available)
The diagnosis of blood cancer requires integration of clinical, pathological, immunophenotypic and genetic / molecular findings. Accurate and consistent interpretation of bone marrow trephines (BMT) is particularly important for distinguishing between important blood cancer subtypes. Such distinction guides patient management and informs risk stratification. In response, our group have developed pioneering artificial intelligence (AI) approaches to accurately capture important tissue features of the bone marrow in blood cancer. This includes the development of automated and quantitative approaches to detect cellular and stromal changes present on routinely prepared diagnostic samples. We are now developing strategies to combine these approaches with newly developed advanced spatial transcriptomic and IHC / IF multiplexing strategies for patient-derived bone marrow biopsies.